Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-11-17 | Amended | $3,385,000 | $465,000 | Debt Only | 06b | SEC link |
| 2025-10-20 | New | $2,920,000 | $2,920,000 | Debt Only | 06b | SEC link |
| 2025-03-14 | New | $2,057,533 | $2,057,533 | Equity Only | 06b | SEC link |
| 2024-09-09 | Amended | $1,540,000 | $1,040,000 | Other | 06b | SEC link |
| 2023-09-13 | New | $500,000 | $500,000 | Other | 06b | SEC link |
| 2021-06-02 | New | Yet to Sell | Unknown | Other | SEC link |
| Name | Role |
|---|---|
| Yobie Benjamin | Director |
| Peter Eckenberg | Director |
| Mark Huber | Director |
| Edward La Cava | Director |
| Ed La Cava | Director |
| Christopher Marsh | Director |
| Thomas Seidel | Director, Executive |
| Thomas Seidl | Director, Executive, Promoter |
| Ken Ward | Director |
| Kenneth Ward | Director |
| Hank Wuh | Director |